Endonovo Therapeutics Inc. ENDVD Archives

TuesdayJan 14, 2020 12:11 pm

QualityStocksNewsBreaks – Endonovo Therapeutics, Inc. (ENDVD) Secures Broad Patent Covering Electromagnetic Treatment of MS

Endonovo Therapeutics (OTCQB: ENDVD) today announced that the United States Patent and Trademark Office (“USPTO”) has issued a U.S. Patent for Application No. 15/549,748 covering method and apparatus for electromagnetic treatment of multiple sclerosis ("MS"). “This issuance follows our prior patents related to the methods of treating post-operative pain and edema,” Endonovo’s Chief Medical Officer and Harvard trained Physical Medicine and Rehabilitation specialist Dr. Nev Zubcevik said in the news release. “The SofPulse(R) technology is research proven and universally applicable to inflammatory conditions. Our preliminary research in the field of Autoimmune Encephalomyelitis - the inflammatory autoimmune model of multiple sclerosis,…

TuesdayJan 07, 2020 11:34 am

QualityStocksNewsBreaks – Endonovo Therapeutics, Inc. (ENDVD) Announces Issuance of U.S. Patent, Expansion of its SofPulse(R) Intellectual Property Portfolio

Endonovo Therapeutics (OTCQB: ENDVD) today announced that the United States Patent and Trademark Office (“USPTO”) has issued U.S. Patent No. 15217855, which is directed to the usage of an Apparatus and Method for Electromagnetic Treatment of Neurological Injury or Condition Caused by a Stroke. “We are extremely pleased with the continued development and expansion of our patent portfolio,” Endonovo Therapeutics CEO Alan Collier said in the news release. “This new issuance continues to expand the breadth and depth of our SofPulse(R) unit intellectual property portfolio and the issuance of this patent is another step in the development of a robust…

MondayDec 23, 2019 11:15 am

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDVD) Provides SofPulse(R) Evaluation Units to All NFL Teams

Endonovo Therapeutics (OTCQB: ENDVD), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, today announced the delivery of SofPulse(R) evaluation units to all thirty-two National Football League (“NFL”) teams. “With injuries affecting the NFL more than any other professional sports league, we are pleased to support the health of NFL players by providing SofPulse(R) evaluation units to all NFL teams,” Endonovo Therapeutics CEO Alan Collier said in the news release. “The SofPulse(R) device is clinically proven to reduce post-operative pain, swelling and need for opioids. Endonovo is committed to helping NFL players get back on the field faster when recovering from…

FridayDec 20, 2019 9:27 am

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDVD) Reverse Split of Common Stock Becomes Effective

Endonovo Therapeutics (OTCQB: ENDVD), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, recently announced that its previously announced 1-for-1,000 reverse split of its common stock became effective as of December 19, 2019. Starting today, December 20, 2019, Endonovo’s common stock will trade on the OTC market under the trading symbol ‘ENDVD’ on a split-adjusted basis for a 20-day period. At the end of the 20 days, the ‘D’ will be removed, and the trading symbol will revert back to ‘ENDV’. “With our sales growth and continued expansion of clients, specifically hospitals, this reverse split is a natural next step in…

Site Search

Company Search

Tag: Endonovo Therapeutics Inc. ENDVD

QualityStocksNewsBreaks – Endonovo Therapeutics, Inc. (ENDVD) Secures Broad Patent Covering Electromagnetic Treatment of MS

QualityStocksNewsBreaks – Endonovo Therapeutics, Inc. (ENDVD) Announces Issuance of U.S. Patent, Expansion of its SofPulse(R) Intellectual Property Portfolio

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDVD) Provides SofPulse(R) Evaluation Units to All NFL Teams

QualityStocksNewsBreaks – Endonovo Therapeutics Inc. (ENDVD) Reverse Split of Common Stock Becomes Effective

Market Basics

Newsletter Publishers

Public Companies